ArticlePloS one2011
Curcumin inhibits neuronal and vascular degeneration in retina after ischemia and reperfusion injury.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 95 citations in OpenAlex.
- Vitamins and nutraceuticals in glaucoma research.European journal of ophthalmology · 2026Review
- Polyphenols and Eye Health: A Narrative Review of the Literature on the Therapeutic Effects for Ocular Diseases.Nutrients · 2025Review
- Therapeutic potential of curcumin in ophthalmic diseases: mechanisms and clinical applications.Journal of translational medicine · 2025Review
- Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Curcumin in Ophthalmology: Mechanisms, Challenges, and Emerging Opportunities.Molecules (Basel, Switzerland) · 2025Review
- Antioxidant effect of gallic acid on retinal ganglion cells in glaucoma model.Scientific reports · 2024Article
- Promising Potential of Curcumin and Related Compounds for Antiviral Drug Discovery.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024Review
- Research Progress on Natural Plant Molecules in Regulating the Blood-Brain Barrier in Alzheimer's Disease.Molecules (Basel, Switzerland) · 2023Review
- Description of a Nonhuman Primate Model of Retinal Ischemia/Reperfusion Injury.Translational vision science & technology · 2023Article
- Role of curcumin in ischemia and reperfusion injury.Frontiers in pharmacology · 2023Review
- Retinal Toxicity Induced by Chemical Agents.International journal of molecular sciences · 2022Review
- Nanoparticles for the treatment of glaucoma-associated neuroinflammation.Eye and vision (London, England) · 2022Review
- Inherited Retinal Dystrophies: Role of Oxidative Stress and Inflammation in Their Physiopathology and Therapeutic Implications.Antioxidants (Basel, Switzerland) · 2022Review
- Role of Curcumin in Retinal Diseases-A review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Review
- Curcumin Facilitates Aryl Hydrocarbon Receptor Activation to Ameliorate Inflammatory Astrogliosis.Molecules (Basel, Switzerland) · 2022Article
- Treatment of Glaucoma with Natural Products and Their Mechanism of Action: An Update.Nutrients · 2022Review
- Investigation into the role of Stmn2 in vascular smooth muscle phenotype transformation during vascular injury via RNA sequencing and experimental validation.Environmental science and pollution research international · 2022Article
- Mecp2 protects kidney from ischemia-reperfusion injury through transcriptional repressing IL-6/STAT3 signaling.Theranostics · 2022Article
- Article
- Anti-inflammatory role of curcumin in retinal disorders (Review).Experimental and therapeutic medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundNeuron loss, glial activation and vascular degeneration are common sequelae of ischemia-reperfusion (I/R) injury in ocular diseases. The present study was conducted to explore the ability of curcumin to inhibit retinal I/R injury, and to investigate underlying mechanisms of the drug effects. METHODOLOGY/PRINCIPAL
findingsDifferent dosages of curcumin were administered. I/R injury was induced by elevating the intraocular pressure for 60 min followed by reperfusion. Cell bodies, brn3a stained cells and TUNEL positive apoptotic cells in the ganglion cell layer (GCL) were quantitated, and the number of degenerate capillaries was assessed. The activation of glial cells was measured by the expression level of GFAP. Signaling pathways including IKK-IκBα, JAK-STAT1/3, ERK/MAPK and the expression levels of β-tubulin III and MCP-1 were measured by western blot analysis. Pre-treatment using 0.01%-0.25% curcumin in diets significantly inhibited I/R-induced cell loss in GCL. 0.05% curcumin pre-treatment inhibited I/R-induced degeneration of retinal capillaries, TUNEL-positive apoptotic cell death in the GCL, brn3a stained cell loss, the I/R-induced up-regulation of MCP-1, IKKα, p-IκBα and p-STAT3 (Tyr), and down-regulation of β-tubulin III. This dose showed no effect on injury-induced GFAP overexpression. Moreover, 0.05% curcumin administered 2 days after the injury also showed a vaso-protective effect. CONCLUSIONS/SIGNIFICANCE: Curcumin protects retinal neurons and microvessels against I/R injury. The beneficial effects of curcumin on neurovascular degeneration may occur through its inhibitory effects on injury-induced activation of NF-κB and STAT3, and on over-expression of MCP-1. Curcumin may therefore serve as a promising candidate for retinal ischemic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.